TNF and B-cell chronic lymphocytic leukemia: The CLL patients treated with GS-1101 monotherapy and combination therapy also showed significantly reduced plasma levels of the chemokines CXCL13, CCL3, CCL4 and cytokine TNFα after 28 days of treatment compared with pretreatment measurements, further suggesting disruption of the CLL microenvironment by GS-1101 (Hoellenriegel et al., 2011; Sharman et al., 2011).